Correlation between Charlson comorbidity index and outcome in patients with chronic phase chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors upfront

Massimo BrecciaDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, ItalyCorrespondence[email protected]

Matteo MolicaDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy

Gioia ColafigliDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy

Irene ZacheoDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy

Roberto LatagliataDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy

Agostino TafuriHematology, S. Andrea Hospital, Rome and Department of Molecular Medicine, Hematology, Sapienza University, Rome, Italy

Giuliana AlimenaDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy

show all

References

Feinstein AR. The pre-therapeutic classification of co-morbidity in chronic disease. J Chron Dis 1970;23:455–468.
PubMedGoogle Scholar
Birim O, Kappetein AP, Bogers AJJC. Charlson comorbidity index as a predictor of long-term outcome after surgery for non-small cell lung cancer. Eur J Cardiothorac Surg 2005;28:759–762.
PubMed Web of Science ®Google Scholar
Breccia M, Latagliata R, Stagno F, et al. Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib. Haematologica 2011;96:1457–1461.
PubMed Web of Science ®Google Scholar
Breccia M, Salaroli A, Serrao A, et al. Application of comorbidity indexes at baseline could be useful to predict rates of response in patients with chronic myeloid leukemia treated with imatinib. Leuk Lymphoma 2014;55:204–206.
PubMed Web of Science ®Google Scholar
Saussele S, Krauss MP, Lauseker M, et al. Comorbidity, measured by the Charlson index, has no negative impact on remission in patients with chronic myeloid leukemia: results of the randomized CML-study IV. Blood 2013;122(Suppl. 1): Abstract 91.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Correlation between Charlson comorbidity index and outcome in patients with chronic phase chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors upfront

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Correlation between Charlson comorbidity index and outcome in patients with chronic phase chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors upfront

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date